We use cookies to make sure that our website works properly, as well as some ‘optional’ cookies to personalise content and advertising, provide social media features and analyse how people use our site. Further information can be found in our Cookies policy
Ledipasvir, a direct-acting antiviral agent, plays a pivotal role in the treatment of hepatitis C virus (HCV) infection, particularly when used in combination with sofosbuvir. Ensuring the accurate estimation of Ledipasvir in bulk and pharmaceutical formulations is essential for maintaining drug quality and therapeutic efficacy. A wide array of analytical methods has been developed for this purpose, ranging from simple spectrophotometric techniques to advanced hyphenated methods such as liquid chromatography-mass spectrometry (LC-MS). This review explores these methods, highlighting their principles, methodologies, and applications. UV-visible spectrophotometry offers a cost-effective and straightforward approach for routine analysis, while chromatographic techniques like high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) are preferred for their precision and specificity. Hyphenated techniques, including LC-MS and HPLC with photodiode array detection, provide unparalleled sensitivity and are crucial for stability studies and pharmacokinetic analyses. Additionally, alternative methods like Fourier-transform infrared spectroscopy and capillary electrophoresis are discussed for their unique applications. Validation of these methods, adhering to ICH guidelines, ensures their reliability and reproducibility. This review also addresses challenges in Ledipasvir estimation, such as interference from excipients and the need for eco-friendly analytical practices. The integration of green chemistry principles into analytical methods is identified as a promising area for future research. Overall, this review provides a comprehensive resource for researchers and professionals aiming to develop and refine analytical techniques for Ledipasvir estimation.
Ledipasvir is a potent antiviral drug that inhibits the NS5A protein, a key component in the replication of hepatitis C virus (HCV). It is predominantly used in combination with sofosbuvir, forming a fixed-dose regimen that has revolutionized the treatment landscape for chronic HCV infection [1]. The drug is highly effective against various HCV genotypes, particularly genotypes 1, 4, 5, and 6, and exhibits a favourable safety and efficacy profile. Its widespread use in therapeutic regimens underscores the necessity for precise and reliable analytical methods to ensure its quality, efficacy and safety [2,3].
Figure 1: Chemical Structure of Ledipasvir
The estimation of Ledipasvir is critical at multiple stages of drug development, including formulation, quality control, and regulatory compliance. Analytical techniques must be robust, sensitive, and reproducible to detect and quantify the drug in diverse matrices, ranging from bulk drug substances to finished pharmaceutical products [4]. Additionally, these methods are essential for identifying impurities, monitoring stability, and evaluating pharmacokinetic properties in biological fluids [5]. Given the complexity of pharmaceutical formulations and the presence of excipients, the development of selective and accurate methods is challenging. Researchers have employed a variety of techniques, including spectrophotometry, chromatography, and advanced hyphenated methods, to overcome these challenges. This review provides a detailed exploration of these analytical methods, highlighting their principles, applications, and roles in ensuring the quality of Ledipasvir in pharmaceutical and clinical settings [6].
MECHANISM OF ACTION
Ledipasvir functions as a direct-acting antiviral agent that specifically targets the NS5A protein of the hepatitis C virus (HCV). NS5A is a multifunctional, phosphoprotein that plays a pivotal role in the viral replication cycle and the assembly of infectious viral particles [7]. By inhibiting NS5A, Ledipasvir disrupts two critical processes in the HCV lifecycle:
Viral RNA Replication: NS5A is essential for the replication of the HCV genome. Ledipasvir binds to a specific domain within the NS5A protein, blocking its ability to recruit other components of the replication complex. This results in the inhibition of RNA synthesis, halting the production of new viral genomes.
Virion Assembly: NS5A also facilitates the assembly and secretion of infectious HCV virions. Ledipasvir's inhibition of NS5A impairs these processes, reducing the production of infectious viral particles [8].
Ledipasvir exhibits pan-genotypic activity, with a higher potency against genotypes 1, 4, 5, and 6. Its mechanism of action is highly synergistic when combined with sofosbuvir, an NS5B polymerase inhibitor. While sofosbuvir prevents RNA chain elongation, Ledipasvir inhibits upstream processes, resulting in a comprehensive blockade of the viral replication cycle. This dual-targeted mechanism not only enhances the antiviral efficacy but also minimizes the emergence of resistant strains, making the combination therapy a cornerstone in the management of chronic HCV infections [9,10].
Reference
Rathod SM and Patel PU: Development and validation for simultaneous estimation of Sofosbuvir and Daclatasvir dihydrochloride in pharmaceutical dosage form by ratio derivative and dual wavelength methods. International Journal of Pharmac Quality Assurance 2020; 11(1): 25-31.
Rani JS and Devanna N: Development and validation of RP-HPLC method for the simultaneous estimation of sofosbuvir, velpatasvir and voxilaprevir in bulk and tablet dosage forms. Ras?yan Journal of Chemistry 2018; 11: 452-59.
Hemdan A and Eissa MS: Simultaneous chromatographic analysis of Sofosbuvir/Ledipasvir in their combined dosage form: an application to green analytical chemistry. J of Anal Science and Technology 2019; 10(39): 1-12.
Baker MM, El-Kafrawy DS, Mahrous MS and Belal TS: Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir. Annales Pharmaceutiques Françaises Journal 2018; 76(1): 16–31.
Rote AP, Alhat J and Kulkarni AA: Development and validation of RP-HPLC method for the simultaneous estimation of ledipasvir and sofosbuvir in bulk and pharmaceutical dosage form. International Journal of Pharmaceutical Sciences and Drug Res 2017; 9(6): 291-98.
Bandla J and Ganapat S: Development and validation of a stability-indicating method for the simultaneous estimation of sofosbuvir and ledipasvir by RP-HPLC. Indian Journal of Pharmaceutical Sciences 2018; 80(6): 1170-76.
Mastanamma SK, Chandini SK, Reehana SK and Saidulu P: Development and validation of stability indicating RPHPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form. Future Journal of Pharmaceutical Sciences 2018; 4(2): 116-123.
Khalili M, Sohrabi MR, Mirzabeygi V and Ziaratgahi TN: Chemometric simultaneous determination of sofosbuvir and ledipasvir in pharmaceutical dosage form. Spectrochimica acta Part A, Molecular and Biomolecular Spectroscopy 2018; 194: 141-51.
Abdulkareem A and El-Tohamy MF: Validated capillary zone electrophoresis approach for simultaneous separation and determination of hepatitis C sofosbuvir and ledipasvir in tablet dosage form. World Journal of Pharmaceutical Research 2017; 6(5): 129-47.
Devi LM, Reddy TR and Abbul K: Simultaneous determination and validation of third generation antiviral drugs by RP-HPLC method. International journal of pharmaceutical analysis and Research 2019; 8: 1-8.
Kothapalli KK, Saisri M, Priyanka M, Subhashini M and Manikanta M: A New Analytical Method Development and Validation for the Simultaneous Estimation of Ledipasvir and Sofosbuvir Using RP-HPLC. Intercontinental Journal of Pharmaceutical Investigation and Research 2017; 4(1):142-165.
Revathi K, Sowndarya G and Swathi V: New RP-HPLC method for simultaneous estimation of sofosbuvir and velpatasvir in combined pharmaceutical dosage forms. International Journal of Advances in Pharmacy and Biotechnology 2020; 6(3): 19-22.
EL-Shorbagy HI, Elsebaei F, Hammad SF, Amina M and El-Brashy: Optimization and modeling of a green dual detected RP-HPLC method by UV and fluorescence detectors using two level full factorial design for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage unit testing. Microchemical Journal 2019; 147: 374-92.
Nehra V, Tan EM, Rizza SA. RP-HPLC method development and validation for the simultaneous estimation of Ledipasvir and Sofosbuvir in fixed dosage form. Int J Pharm Sci Res. 2016;7(3):1260-1265.
Patro S, Kumar SH, Barathkumar M, Masthaniah E, Sairam K, Prem Sumanth Kumar S. A new analytical method for determination of Ledipasvir and Sofosbuvir in tablet dosage form. Int J Res Pharm Chem Anal. 2020;6(1):101-107.
El-Bagary RI, Elkady EF, Ayoub BM. Liquid chromatography–tandem mass spectrometry method for the simultaneous determination of Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in their dosage forms. J AOAC Int. 2020;103(6):1582-1590.
Kumar V, Supriya T, Sivagami B, Sireesha R, Charan Kumar R, Niranjan Babu M. Development and validation of new analytical method for the simultaneous estimation of Ibuprofen and Diphenhydramine in bulk and pharmaceutical dosage form by RP-HPLC. Int J Res Pharm Chem Anal. 2018;1(1):1-7.
Salomi P, Shobha Rani P, Ravindra Reddy K, Afreen Sultana. A robust stability indicating HPLC technique for evaluation of Pibrentasvir and Glecaprevir in tablet dosage form. Int J Res Pharm Chem Anal. 2020;1(4):1-7.
Pavan Kumar V. Stability indicating RP-HPLC method development and validation for the simultaneous estimation of Grazoprevir and Elbasvir in bulk and pharmaceutical dosage form. Int J Res Pharm Chem Anal. 2018;1(1):8-14.
Jayakumar A. Development and validation of RP-HPLC method for the simultaneous estimation of Valsartan and Sacubitril in pharmaceutical dosage form. Int J Res Pharm Chem Anal. 2023;2(1):1-7.
El-Bagary RI, Elkady EF, Ayoub BM. Liquid chromatography–tandem mass spectrometry method for the simultaneous determination of Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in their dosage forms. J AOAC Int. 2020;103(6):1582-1590.
Patel SK, Patel NJ, Patel SA. Development and validation of stability-indicating RP-HPLC method for simultaneous estimation of Sofosbuvir and Ledipasvir in tablet dosage form. World J Pharm Pharm Sci. 2016;5(5):775-792.
Sahoo MK, Giri RK, Barik CS, Kanungo SK. Development and validation of a stability-indicating RP-HPLC method for simultaneous estimation of Sofosbuvir and Ledipasvir in combined tablet dosage form. Int J Pharm Sci Res. 2016;7(12):4949-4955.
Rao BM, Srinivasu P, Kumar PR, Raju NA, Rao NS, Mukkanti K. Development and validation of a specific stability-indicating high-performance liquid chromatographic method for related compounds and assay of Ledipasvir. J Chromatogr Sci. 2016;54(4):647-653.
Rao BM, Srinivasu P, Kumar PR, Raju NA, Rao NS, Mukkanti K. Development and validation of a specific stability-indicating high-performance liquid chromatographic method for related compounds and assay of Ledipasvir. J Chromatogr Sci. 2016;54(4):647-653.
Srinivasu P, Rao BM, Kumar PR, Raju NA, Rao NS, Mukkanti K. A novel stability-indicating RP-HPLC method for the determination of Ledipasvir in bulk and pharmaceutical dosage forms. Der Pharm Lett. 2016;8(2):457-464.
Shital Gadekar
Corresponding author
Department of Pharmaceutical Quality Assurance, SND College of Pharmacy, Babhulgaon (Yeola), India
Department of Pharmaceutical Quality Assurance, SND College of Pharmacy, Babhulgaon (Yeola), India
Shital Gadekar*, Dr. Raju Bathula, Review on Various Analytical Methods for Estimation of Ledipasvir From Its Bulk and Pharmaceutical Formulation, Int. J. Sci. R. Tech., 2025, 2 (7), 207-215. https://doi.org/10.5281/zenodo.15860522
10.5281/zenodo.15860522
